Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention

Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention

Essentials Acquired hemophilia A is a rare bleeding disorder often accompanied by other comorbidities. We describe emicizumab use in acquired hemophilia A complicated by acute coronary syndrome. Emicizumab proved safe and effective in a patient with acquired hemophilia A. Emicizumab facilitated succ...

Full description

Bibliographic Details
Main Authors: Kathryn E. Dane, John P. Lindsley, Michael B. Streiff, Alison R. Moliterno, Mian K. Khalid, Satish Shanbhag
Format: Article
Language:English
Published: Elsevier 2019-07-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
acute coronary syndrome
blood coagulation factor inhibitors
coronary artery disease
hemophilia A
platelet aggregation inhibitors
Online Access:https://doi.org/10.1002/rth2.12201

Internet

https://doi.org/10.1002/rth2.12201

Similar Items